EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2.

Oncogene · 2026 · PMC12846922 · PMID 41501210

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These findings are highly significant as they revealed a critical mechanism underlying the lack of efficacy data of many previously reported EZH2 PROTACs in inhibiting PCa cells [ 19 , 20 , 23 , 26 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.